Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228255 | 0.84 | HDAC3 (0.59) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL5224456 | 0.83 | HDAC3 (0.58) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL5226372 | 0.82 | HDAC2 (0.61) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL5226083 | 0.82 | HDAC1 (0.67) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL5228076 | 0.81 | HDAC2 (0.74) | HDAC3HDAC2HDAC1 | |
| SCHEMBL6337934 | 0.77 | HDAC2 (0.53) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL5224342 | 0.75 | HDAC1 (0.70) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL5224592 | 0.74 | HDAC1 (0.72) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL3576103 | 0.73 | POLB (0.53) | HDAC3HDAC2HDAC1HDAC4HDAC7 | |
| SCHEMBL20304929 | 0.72 | HDAC1 (0.72) | HDAC3HDAC2HDAC1HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501508-B1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050222410-A1 | Inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1501508-A1 | INHIBITORS OF HISTONE DEACETYLASE | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092686-A1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222410-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | HDAC3 2/4885HDAC2 4/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.